Daewoong to transfer techs for autoimmune disease to US pharma

It signs an export agreement with Vitali Bio for development and commercialization rights of DWP213388

Daewoong Pharmaceutical's office building
Daewoong Pharmaceutical's office building
Min Su Han 1
2023-04-28 10:21:00 hms@hankyung.com
Bio & Pharma


South Korea's Daewoong Pharmaceutical announced on Friday that it has signed a technology export contract for the clinical development and commercialization rights of DWP213388, an autoimmune disease treatment, with US-based Vitali Bio.

The deal is worth up to a maximum of 640 billion won ($478 million), including an upfront payment of 14.7 billion won. The milestone payment based on clinical development and sales is up to 620 billion won. The technology usage fee (royalty) proportional to net sales is separate.

Vitali has acquired the rights to DWP213388 worldwide, except for Korea, Indonesia, Thailand, the Philippines, Vietnam and Malaysia.

The main indication of DWP213388 is autoimmune diseases, which are conditions that occur when the immune system attacks normal cells inside the body. DWP213388 is an orally administered treatment that simultaneously inhibits B cells and T cells, both of which are immune cells. It has received US Food and Drug Administration (FDA) approval for phase 1 clinical trials.

The latest contract also includes an option for Daewoong to transfer the technology of two candidate substances it is developing. If the option is exercised, the total technology export amount is 1.26 trillion won.

Write to Min Su Han at hms@hankyung.com
#Daewoong Pharmaceutical #DWP213388 #autoimmune disease treatment #Vitali Bio #technology transfer

Daewoong Pharma, UK firm to jointly develop autoimmune disease drug

Daewoong Pharma, UK firm to jointly develop autoimmune disease drug

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday that it has signed a cooperation agreement with Sygnature Discovery, a British new drug developer, to discover new candidate substances for autoimmune disease treatments.Under the agreement, Daewoong Pharmaceutical will use Syg

Daewoong wins approval for GERD treatment Fexuclu in Chile

Daewoong wins approval for GERD treatment Fexuclu in Chile

Daewoong's Fexuclue South Korean pharmaceutical company Daewoong Pharmaceutical announced on Tuesday that it has received marketing authorization from Chile's National Medicines Agency Department (ANAMED) within the Public Health Institute for its gastroesophageal reflux disease drug (GERD) Fex

Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico

Korea's Daewoong to export diabetes drug Envlo to Brazil, Mexico

Daewoong Pharmaceutical headquarters in Seoul (Courtesy of Daewoong) South Korea’s Daewoong Pharmaceutical Co. said on Feb. 24 it is set to embark on global sales of Envlo, a new drug for diabetes, by exporting it to Brazil and Mexico.Through the $84.4 million deal, the Korean biotech w

Korean court rules Daewoong poached Medytox’s botox strain

Korean court rules Daewoong poached Medytox’s botox strain

Korean botox maker Medytox A South Korean court on Friday ruled in favor of Medytox Inc. in a civil lawsuit against its crosstown rival Daewoong Pharmaceutical Co. over the source of its botulinum toxin, more commonly known as botox.The Seoul Central District Court accepted Medytox’s clai
(* comment hide *}